US Medicine Magazine Highlights CyPath Lung as Promising Tool for Lung Cancer Detection in Veterans, Reducing Costs to VA

U.S. Medicine magazine has featured bioAffinity Technologies' CyPath Lung test as a promising tool to improve lung cancer detection in veterans and lower costs for the Department of Veterans Affairs (VA). The noninvasive diagnostic has shown high diagnostic performance and the potential to reduce unnecessary interventions and their risks. Economic modeling showed savings of nearly $895 million for private payers and $379 million for Medicare if CyPath Lung had been part of the standard of care in 2022.